Maria Messeri
YOU?
Author Swipe
View article: Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction Open
Introduction: Despite the approval of novel agents that have significantly improved long-term survival rates for multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), most patients eventually relapse. The failur…
View article: Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports Open
Background Thrombotic microangiopathy (TMA) is a pathological syndrome characterized by a combination of three key features: microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ damage, primarily affecting the kidneys. The…
View article: P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
P17 CLONAL PLASMA-CELLS IN STEM CELL APHERESIS AS A PREDICTOR OF PROGRESSION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELEGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION Open
Background: Flow-cytometry is considered crucial for monitoring multiple myeloma (MM) patients, in particularly for evaluation of minimal residual disease (MRD) [1]. Routinely MRD on bone marrow aspirate is the optimal method for assessing…
View article: P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
P22 THE PROGNOSTIC ROLE OF 1Q ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS Open
Background: Additional copies of chromosome 1q (+1q) is one of the most common cytogenetic abnormalities in multiple myeloma, with a frequency in newly diagnosed patients (NDMM) around 30-50%. However, its prognostic impact is still debate…
View article: P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM) Open
Background: In recent years, the clinical outcome of multiple myeloma (MM) patients has improved due to the introduction of several new agents, such as the third-generation immunomodulator, the next-generation proteasome inhibitors (PIs) a…
View article: Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network Open
Introduction Carfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies …